JP2019516756A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2019516756A5 JP2019516756A5 JP2018561528A JP2018561528A JP2019516756A5 JP 2019516756 A5 JP2019516756 A5 JP 2019516756A5 JP 2018561528 A JP2018561528 A JP 2018561528A JP 2018561528 A JP2018561528 A JP 2018561528A JP 2019516756 A5 JP2019516756 A5 JP 2019516756A5
- Authority
- JP
- Japan
- Prior art keywords
- weeks
- composition according
- patient
- disease
- compound
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 150000001875 compounds Chemical class 0.000 claims 6
- 208000024891 symptom Diseases 0.000 claims 5
- 208000020925 Bipolar disease Diseases 0.000 claims 3
- 201000011240 Frontotemporal dementia Diseases 0.000 claims 3
- 208000030886 Traumatic Brain injury Diseases 0.000 claims 3
- 208000024714 major depressive disease Diseases 0.000 claims 3
- 230000000926 neurological effect Effects 0.000 claims 3
- 208000020016 psychiatric disease Diseases 0.000 claims 3
- 208000024827 Alzheimer disease Diseases 0.000 claims 2
- 206010002942 Apathy Diseases 0.000 claims 2
- 206010008190 Cerebrovascular accident Diseases 0.000 claims 2
- 208000018737 Parkinson disease Diseases 0.000 claims 2
- 208000006011 Stroke Diseases 0.000 claims 2
- 239000000935 antidepressant agent Substances 0.000 claims 2
- 229940005513 antidepressants Drugs 0.000 claims 2
- 208000029560 autism spectrum disease Diseases 0.000 claims 2
- 208000026106 cerebrovascular disease Diseases 0.000 claims 2
- 201000000980 schizophrenia Diseases 0.000 claims 2
- 230000009529 traumatic brain injury Effects 0.000 claims 2
- 208000007415 Anhedonia Diseases 0.000 claims 1
- 206010012289 Dementia Diseases 0.000 claims 1
- 206010014557 Emotional poverty Diseases 0.000 claims 1
- 206010014612 Encephalitis viral Diseases 0.000 claims 1
- 206010024264 Lethargy Diseases 0.000 claims 1
- 208000036831 Moderate mental retardation Diseases 0.000 claims 1
- 206010041243 Social avoidant behaviour Diseases 0.000 claims 1
- 201000007201 aphasia Diseases 0.000 claims 1
- 206010013663 drug dependence Diseases 0.000 claims 1
- 230000000694 effects Effects 0.000 claims 1
- 238000000034 method Methods 0.000 claims 1
- 150000003839 salts Chemical class 0.000 claims 1
- 230000000698 schizophrenic effect Effects 0.000 claims 1
- 239000012453 solvate Substances 0.000 claims 1
- 208000011117 substance-related disease Diseases 0.000 claims 1
- 208000011580 syndromic disease Diseases 0.000 claims 1
- 201000008914 temporal lobe epilepsy Diseases 0.000 claims 1
- 230000001225 therapeutic effect Effects 0.000 claims 1
- 201000002498 viral encephalitis Diseases 0.000 claims 1
Priority Applications (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2022160201A JP2022188185A (ja) | 2016-05-25 | 2022-10-04 | 非統合失調症患者の陰性症状を治療するための方法および組成物 |
| JP2024173054A JP2025000921A (ja) | 2016-05-25 | 2024-10-02 | 非統合失調症患者の陰性症状を治療するための方法および組成物 |
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201662341590P | 2016-05-25 | 2016-05-25 | |
| US62/341,590 | 2016-05-25 | ||
| PCT/US2017/034030 WO2017205393A1 (en) | 2016-05-25 | 2017-05-23 | Compositions and methods for treating negative symptoms in non-schizophrenic patients |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022160201A Division JP2022188185A (ja) | 2016-05-25 | 2022-10-04 | 非統合失調症患者の陰性症状を治療するための方法および組成物 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2019516756A JP2019516756A (ja) | 2019-06-20 |
| JP2019516756A5 true JP2019516756A5 (enExample) | 2020-07-02 |
Family
ID=58794265
Family Applications (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2018561528A Pending JP2019516756A (ja) | 2016-05-25 | 2017-05-23 | 非統合失調症患者の陰性症状を治療するための方法および組成物 |
| JP2022160201A Pending JP2022188185A (ja) | 2016-05-25 | 2022-10-04 | 非統合失調症患者の陰性症状を治療するための方法および組成物 |
| JP2024173054A Withdrawn JP2025000921A (ja) | 2016-05-25 | 2024-10-02 | 非統合失調症患者の陰性症状を治療するための方法および組成物 |
Family Applications After (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022160201A Pending JP2022188185A (ja) | 2016-05-25 | 2022-10-04 | 非統合失調症患者の陰性症状を治療するための方法および組成物 |
| JP2024173054A Withdrawn JP2025000921A (ja) | 2016-05-25 | 2024-10-02 | 非統合失調症患者の陰性症状を治療するための方法および組成物 |
Country Status (9)
| Country | Link |
|---|---|
| US (2) | US20190216793A1 (enExample) |
| EP (1) | EP3463356A1 (enExample) |
| JP (3) | JP2019516756A (enExample) |
| KR (2) | KR20240005110A (enExample) |
| CN (3) | CN113694065A (enExample) |
| PH (1) | PH12018502445A1 (enExample) |
| SG (2) | SG11201810358YA (enExample) |
| TW (2) | TWI820001B (enExample) |
| WO (1) | WO2017205393A1 (enExample) |
Families Citing this family (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2018501217A (ja) | 2014-12-02 | 2018-01-18 | 田辺三菱製薬株式会社 | 統合失調症を治療するための２−（（１−（２（４−フルオロフェニル）−２−オキソエチル）ピペリジン−４−イル）メチル）イソインドリン−１−オン |
| CA3067031A1 (en) | 2017-06-21 | 2018-12-27 | Minerva Neurosciences, Inc. | Gastro-resistant controlled release oral dosage forms |
| MA53437A (fr) * | 2018-08-21 | 2021-06-30 | Minerva Neurosciences Inc | Utilisation de rolupéridone pour traiter des symptômes et des troubles négatifs, augmenter la neuroplasticité et favoriser la neuroprotection |
| TWI879755B (zh) * | 2020-02-20 | 2025-04-11 | 日商田邊三菱製藥股份有限公司 | 魯哌啶酮用於治療負性症狀及疾病、增加神經可塑性及促進神經保護的用途 |
| KR102360137B1 (ko) * | 2020-03-25 | 2022-02-08 | 주식회사 케이티앤지 | 카트리지 및 이를 포함하는 에어로졸 생성 장치 |
| PE20231815A1 (es) * | 2021-02-09 | 2023-11-16 | Xenon Pharmaceuticals Inc | Abridor de canales de potasio controlado por voltaje para uso en el tratamiento de la anhedonia |
| US20240212824A1 (en) * | 2022-12-21 | 2024-06-27 | Woebot Labs, Inc. | Administering a digital therapeutic using a device interface to treat anxiety or depression |
Family Cites Families (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| IL151533A0 (en) | 2000-02-29 | 2003-04-10 | Mitsubishi Pharma Corp | Novel cyclic amide derivatives |
| TW200616608A (en) * | 2004-07-09 | 2006-06-01 | Forest Laboratories | Memantine as adjunctive treatment to atypical antipsychotics in schizophrenia patients |
| CN101378752A (zh) * | 2006-02-07 | 2009-03-04 | 田边三菱制药株式会社 | 4-酰氨基吡啶衍生物介导的神经发生 |
| KR20080089279A (ko) * | 2007-03-30 | 2008-10-06 | 미쓰비시 타나베 파마 코퍼레이션 | 우울증의 예방 및/또는 치료제 |
| US8937900B2 (en) * | 2010-07-20 | 2015-01-20 | Qualcomm Incorporated | Enhancing pilot channel transmission in TD-SCDMA multicarrier systems using secondary carrier frequencies |
| DK2595484T3 (en) * | 2010-07-20 | 2018-01-22 | Minerva Neurosciences Inc | USE OF CYCLIC AMIDE DERIVATIVES FOR TREATMENT OF SLEEP DISORDERS |
| WO2012012543A1 (en) * | 2010-07-20 | 2012-01-26 | Cyrenaic Pharmaceuticals Inc. | Methods of use cyclic amide derivatives to treat sigma receptor-mediated disorders |
| US9737531B2 (en) * | 2012-07-12 | 2017-08-22 | Glytech, Llc | Composition and method for treatment of depression and psychosis in humans |
| EP3144308B1 (en) * | 2014-05-16 | 2020-06-24 | Takeda Pharmaceutical Company Limited | Nitrogen-containing heterocyclic compound |
| JP2018501217A (ja) * | 2014-12-02 | 2018-01-18 | 田辺三菱製薬株式会社 | 統合失調症を治療するための２−（（１−（２（４−フルオロフェニル）−２−オキソエチル）ピペリジン−４−イル）メチル）イソインドリン−１−オン |
-
2017
- 2017-05-23 CN CN202111014262.XA patent/CN113694065A/zh active Pending
- 2017-05-23 CN CN201780045461.2A patent/CN109689055A/zh active Pending
- 2017-05-23 US US16/302,722 patent/US20190216793A1/en not_active Abandoned
- 2017-05-23 EP EP17726525.3A patent/EP3463356A1/en not_active Withdrawn
- 2017-05-23 TW TW106117023A patent/TWI820001B/zh active
- 2017-05-23 WO PCT/US2017/034030 patent/WO2017205393A1/en not_active Ceased
- 2017-05-23 SG SG11201810358YA patent/SG11201810358YA/en unknown
- 2017-05-23 KR KR1020237043697A patent/KR20240005110A/ko not_active Ceased
- 2017-05-23 CN CN202111014298.8A patent/CN113908156A/zh active Pending
- 2017-05-23 JP JP2018561528A patent/JP2019516756A/ja active Pending
- 2017-05-23 SG SG10202011470UA patent/SG10202011470UA/en unknown
- 2017-05-23 KR KR1020187036656A patent/KR20190013846A/ko not_active Ceased
- 2017-05-23 TW TW112118953A patent/TWI851224B/zh active
-
2018
- 2018-11-20 PH PH12018502445A patent/PH12018502445A1/en unknown
-
2022
- 2022-05-26 US US17/825,783 patent/US20230190726A1/en not_active Abandoned
- 2022-10-04 JP JP2022160201A patent/JP2022188185A/ja active Pending
-
2024
- 2024-10-02 JP JP2024173054A patent/JP2025000921A/ja not_active Withdrawn
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2021105032A5 (enExample) | ||
| JP2020514317A5 (enExample) | ||
| JP2014502641A5 (enExample) | ||
| FI3856341T3 (fi) | (s)-1-(4-fluorifenyyli)-1-(2-(4-(6-(1-metyyli-1h-pyratsol-4-yyli)pyrrolo[2,1-f][1,2,4]triatsin-4-yyli)piperatsinyyli)pyrimidin-5-yyli)etaani-1-amiinin kidemuotoja ja valmistusmenetelmiä | |
| JP2022502500A5 (enExample) | ||
| JP2017531020A5 (enExample) | ||
| JP2013545730A5 (enExample) | ||
| JP2022549335A5 (enExample) | ||
| JP2021525729A5 (enExample) | ||
| JP2019535723A5 (enExample) | ||
| RU2013154699A (ru) | Сцилло-инозитол для применения в лечении поведенческих и психических расстройств | |
| JP2016503010A5 (enExample) | ||
| MA55199B1 (fr) | (n-)acétyl-l-leucine pour le traitement des lésions cérébrales traumatiques | |
| RU2010140613A (ru) | Амиды диазабициклоалканов, селективные в отношении подтипа никотиновых ацетилхолиновых рецепторов | |
| JP2019534327A5 (enExample) | ||
| JP2015522018A5 (enExample) | ||
| JP2024515829A5 (enExample) | ||
| RU2012108656A (ru) | Применение 4-аминопиридина для улучшения состояния при нейрокогнитивном и/или нейропсихиатрическом нарушении у пациентов с демиелинизирующими и другими заболеваниями нервной системы | |
| JP2011518168A5 (enExample) | ||
| WO2018005794A3 (en) | Novel non-systemic tgr5 agonists | |
| JP2021530543A5 (enExample) | ||
| PH12018502445A1 (en) | Compositions and methods for treating negative symptoms in non-schizophrenic patients | |
| JP2023553253A5 (enExample) | ||
| JPWO2021153665A5 (enExample) | ||
| JP2017502069A5 (enExample) |